- AdventHealth Research Institute
A new study reveals that people newly diagnosed with Type 2 diabetes face a significantly higher risk of developing aggressive cancers—including those of the liver, pancreas, and colon.
While obesity has long been linked to these cancers, the research suggests Type 2 diabetes itself may be an independent driver of cancer risk. The findings, presented at the 2025 European Congress on Obesity, analyzed data from over 23,000 people in the U.K. Biobank with new-onset Type 2 diabetes and compared them to more than 71,000 non-diabetic individuals of similar age, sex, and weight.
Over five years, cancer risk was clearly higher in the diabetes group:
- Liver cancer risk was nearly 4 times higher in men and 5 times higher in women.
- Pancreatic cancer risk rose 74% in men, nearly doubled in women.
- Colorectal cancer risk increased by more than 25% in both groups.
Lead author Owen Tipping from the University of Manchester said the link may stem from factors like inflammation, insulin resistance, or gut microbiome changes—beyond just excess weight.
Experts say more research is needed but agree the findings highlight the importance of early detection, healthy lifestyle changes, and ongoing monitoring. “This isn’t a reason to panic,” said oncologist Dr. Jack Jacoub. “It’s a reason to take action—through diet, exercise, and good blood sugar control.”
The takeaway? Type 2 diabetes may do more than disrupt blood sugar—it could quietly raise your cancer risk too.
Recent News
The Next Frontier: Preventing Type 1 Diabetes Before It Starts
Recent research led by AdventHealth’s Translational Research Institute and others reveals that Type 1 diabetes develops gradually and can now be detected early through blood tests, opening the door to...
Advancing Heart Care: A New Chapter with the BrioVAD Study
The AdventHealth Research team recently completed Core Training for the INNOVATE 2254936 Vidic trial, bringing this novel device to AdventHealth.
AdventHealth Launches NIH-Funded THRIVE Trial to Address Apathy in Late-Life Depression
AdventHealth Neuroscience Institute is launching THRIVE, a new NIH-funded clinical trial led by geriatric neuropsychologist and neuroscience researcher Lauren Oberlin, PhD.
AdventHealth Leads the Nation in STAR Trial Enrollment
AdventHealth Research Institute (AHRI) is proud to be the highest enrolling site in the United States for the STAR trial.
Gut Microbes, Diet, and Energy: New Clues for Tackling Energy Balance
A controlled dietary study found that a high-fiber, microbiome-enhancing diet altered gut metabolites, reduced energy absorption, and unexpectedly mimicked fasting effects, offering new insights into...
Can Exercise Turn Back the Clock on Your Brain? New Study Says Yes
What if hitting the gym could actually make your brain younger? A new study suggests it can. Our research group found that adults who committed to a year of moderate-to-vigorous aerobic exercise—like...
Dr. Kirk Erickson Featured on Fox 35 to Talk About the Connection Between Physical Activity and Brain Health
AdventHealth Research Institutes own Dr. Kirk Erickson was recently featured on Fox 35 to talk about the connection between physical activity and brain health.
Conform Trial: Major Milestone Achieved
On August 8, 2025, our team successfully completed the very first implant day for the Conform Clinical Trial, enrolling and treating our first three patients with the Conformal CLAAS System for Left...
Dr. Vipul Patel Performs the Longest Distance Telesurgery Ever Completed
In our latest Clinician’s View, Dr. Patel shares his team’s telesurgery journey, including how they are ensuring safety, quality and ethical exploration of this innovative approach.
AdventHealth’s Dr. Stephanie Compton Featured in ACS Highlight on Diet and Cancer Treatment
We’re proud to announce that Stephanie Compton, PhD, a valued post‑doctoral researcher at the AdventHealth Research Institute, was recently featured by the American Cancer Society.
Back-to-School with Type 1 Diabetes
Starting school is exciting and for families managing T1D, a little planning can make all the difference.
New Study Enrolling: RISE - Treating Ulcerative Colitis
We are proud to announce the launch of the new RISE study.